Naltrexone (50 mg) plus psychotherapy in alcohol-dependent patients: A meta-analysis of randomized controlled trials

American Journal of Drug and Alcohol Abuse

Volumn 39, Issue 3, 2013, Pages 144-160

  Jarosz, Joanna ^a   Miernik, Katarzyna ^a   Wa̧chal, Maria ^a   Walczak, Jacek ^a   Krumpl, Günther ^b  

^a Arcana Institute   (Poland)

^b Medical Research Network GmbH   (Austria)

Author keywords

Alcohol dependency; Naltrexone; Placebo; Psychotherapy; Systematic review

Indexed keywords

ALCOHOL; NALTREXONE; NICOTINE; PLACEBO;

ABDOMINAL PAIN; ALCOHOL ABSTINENCE; ALCOHOLISM; ANXIETY; ARTICLE; CLINICAL ASSESSMENT; CLINICAL EFFECTIVENESS; DIARRHEA; DIZZINESS; DRUG SAFETY; DRUG WITHDRAWAL; DSM-IV; FATIGUE; HEADACHE; HUMAN; INSOMNIA; META ANALYSIS; NAUSEA; NIGHTMARE; PRACTICE GUIDELINE; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; SIDE EFFECT; SOMNOLENCE; SYSTEMATIC REVIEW (TOPIC); TOBACCO DEPENDENCE; TREATMENT OUTCOME; VOMITING;

ALCOHOLISM; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 84878464519     PISSN: 00952990     EISSN: 10979891     Source Type: Journal    
DOI: 10.3109/00952990.2013.796961     Document Type: Article

References (50)

1. American Psychiatric Association. Task Force on DSM-IV Diagnostic and Statistical Manual of Mental Disorders: DSM-IV-TR (4th ed.). Washington, DC: American Psychiatric Association, 2000.
2. Swift RM. Drug therapy for alcohol dependence. N Engl J Med 1999; 340(19):1482-1490.
3. Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996; 91 (12):1773-1796.
4. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M. Opioid antagonist for alcohol dependence. Cochrane Database Syst Rev 2010; 12: CD001867.
5. Anton RE, O'Malley SS, Ciraulo RA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, Longabaugh R, Mason BJ, Mattson MF, Miller WR, Pettinati HM, Randall CL, Swift R, Weiss RD, Williams LD, Zweben A. Combined pharmacotherapies and behavioral interventions for alcohol dependence. JAMA 2006; 295 (17):2003-2017.
6. Schaffer A, Naranjo CA. Recommended drug treatment strategies for the alcoholic patient. Drugs 1998; 56(4):571-585.
7. Swift R, Oslin DW, Alexander M, Forman R. Adherence monitoring in naltrexone pharmacotherapy trials: a systematic review. J Stud Alcohol Drugs 2011; 72(6):1012-1018.
8. Litten RZ, Allen JP. Advances in development of medications for alcoholism treatment. Psychopharmacology (Berl) 1998; 139(1-2):20-33.
9. Pettinati HM, O'Brien CP, Rabinowitz AR, Wortman SM, Oslin DW, Kampman KM, Dackis CA. The status of nal-trexone in the treatment of alcohol dependence specific effect on heavy drinking. J Clin Psychopharmacol 2006; 26 (6):610-625.
10. Roozen HG, de Waart R, van der Windt DAWM, van den Brink W, de Jong CAJ, Kerkhof AJFM. A systematic review of the effectiveness of naltrexone in the maintenancetreatment of opioid and alcohol dependence. Eur Neuropsychopharmacol 2006; 16(5):311-323.
11. Rösner S, Hackl-Herrwerth A, Leucht S, Vecchi S, Srisurapanont M, Soyka M Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2010; 12:CD001867
12. Rösner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008; 22(1):11-23.
13. Bouza C, Angeles M, Munoz A, Amate JM. Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 2004; 99(7): 811-828.
14. Higgins JPT, Green S (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.1. The Cochrane Collaboration, 2009
15. Agencja Oceny Technologii Medycznych. Wytyczne Przeprowadzania Oceny Technologii Medycznych (HTA). Kraków-Warszawa, 2009.
16. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17(1):1-12.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188.
18. Peacock P, Peacock J. Oxford Handbook of Medical Statistics. Oxford University Press, 2010.
19. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th ed.). Washington DC: American Psychiatric Association, 1994; American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (3rd ed.). Washington DC: American Psychiatric Association, 1987.
20. Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, Labriola D, Marshall J, Moncrieff J, Morgan MY, Peters T, Ritson B. A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 2000; 35(6):587-593.
21. Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, Wetterling T, Kielstein V, Labriola D, Croop R. Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 2002; 22(6):592-598.
22. Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP. Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 1992; 49(11):876-880.
23. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 1997; 54(8):737-742.
24. Volpicelli JR, Clay KL, Watson NT, O'Brien CP. Naltrexone in the treatment of alcoholism: predicting response to naltrexone. J Clin Psychiatry 1995; 56(Suppl 7):39-44.
25. Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK. Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 1999; 156(11):1758-1764.
26. Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK, Roberts JS. Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 2001; 21(1):72-77.
27. Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, Weltman M, Bell JR, Richardson K, Haber PS. Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006; 101(10):1451-1462.
28. Huang M-C, Chen C-H, Yu J-M, Chen C-C. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan. Addict Biol 2005; 10(3):289-292.
29. Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA. Naltrexone in the treatment of alcohol dependence. N Engl J Med 2001; 345(24):1734-1739.
30. Cramer JA, Rosenheck R, Kirk G, Krol W, Krystal J. Naltrexone Study Group 425. Medication compliance feedback and monitoring in a clinical trial: predictors and outcomes. Value Health 2003; 6(5):566-573.
31. Ahmadi J, Ahmadi N. A double blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence. Ger J Psychiatr 2002; 5(4):85-89.
32. Baltieri DA, Daró FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; 103(12):2035-2044.
33. O'Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, Romano D, Robinson J, Meandzija B, Stillner V, Wu R, Goldman D. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin and Exp Res 2008; 32(7):1271-1283.
34. Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, Thevos A, Wang W, Woolson R. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 2005; 25 (4):349-357.
35. Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, Mengual I, Gonzalvo B, Segura L, Trujols J, Casas M. A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 2002; 26(9):1381-1387.
36. Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Wiedemann K. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60(1):92-99.
37. Kiefer F, Jahn H, Holzbach R, Briken P, Stracke R, Wiedemann K. The NALCAM-study: efficacy, tolerability, outcome. Sucht 2003; 49:342-351.
38. Latt NC, Jurd S, Houseman J, Wutzke SE. Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 2002; 176(11):530-534.
39. Morris PLP, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial. Addiction 2001; 96(11):1565-1573.
40. O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 1992; 49 (11):881-887.
41. O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B. Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 1996; 53(3):217-224.
42. Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, Gustafsson L, Halldin J, Nilsson L-H, Stolt G, Willander A. A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 2003; 27(7):1142-1149.
43. Ahmadi J, Babaeebeigi M, Maany I, Porter J, Mohagheghzadeh M, Ahmadi N, Dehbozorgi G. Naltrexone for alcohol-dependent patients. Ir J Med Sci 2004; 173(1):34-37.
44. Streeton C, Whelan G. Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials. Alcohol Alcohol 2001; 36 (6):544-552.
45. Kranzler HR, Van Kirk J. Efficacy of naltrexone and acampro-sate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 2001; 25(9):1335-1341.
46. Snyder JL, Bowers TG. The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence: a relative benefits analysis of randomized controlled trials. Am J Drug Alcohol Abuse 2008; 34(4):449-461.
47. Srisurapanont M, Jarusuraisin N. Opioid antagonist for alcohol dependence. Cochrane Database Syst Rev 2002; 2: CD001867.
48. Gueorguieva R, Wu R, Pittman B, Cramer J, Rosenheck RA, O'Malley SS, Krystal JH. New insights into the efficacy of naltrexone based on trajectory-based reanalyses of two negative clinical trials. Biol Psychiatry 2007; 61 (11):1290-1295.
49. Krystal JH, Gueorguieva R, Cramer J, Collins J, Rosenheck R, VA CSP No. 425 Study Team. Naltrexone is associated with reduced drinking by alcohol dependent patients receiving antidepressants for mood and anxiety symptoms: results from VA Cooperative Study No. 425, "Naltrexone in the treatment of alcoholism". Alcohol Clin Exp Res 2008; 32(1):85-91.
50. Rubio G, Jimenez-Arriero MA, Ponce G, Palomo. Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 2001; 36(5):419-425.